Insmed, Inc. (NASDAQ:INSM – Get Free Report) saw some unusual options trading on Thursday. Investors acquired 7,564 call options on the stock. This represents an increase of 85% compared to the typical volume of 4,092 call options.
Insmed Stock Up 15.4%
Insmed stock traded up $18.44 during midday trading on Thursday, hitting $138.24. The stock had a trading volume of 5,431,994 shares, compared to its average volume of 2,984,080. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77. The stock has a market cap of $30.33 billion, a P/E ratio of -49.39 and a beta of 0.83. Insmed has a 12 month low of $90.39 and a 12 month high of $212.75. The business has a fifty day moving average price of $110.51 and a 200 day moving average price of $122.84.
Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The firm had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. During the same quarter in the previous year, the company earned ($1.75) EPS. The company’s quarterly revenue was up 268.4% compared to the same quarter last year. Research analysts predict that Insmed will post -1.86 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on INSM shares. Morgan Stanley lowered their price objective on Insmed from $218.00 to $213.00 and set an “overweight” rating for the company in a research note on Wednesday, October 21st. BMO Capital Markets restated an “outperform” rating on shares of Insmed in a report on Tuesday, October 6th. JPMorgan Chase & Co. cut their target price on Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, August 10th. Wells Fargo & Company increased their target price on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, The Goldman Sachs Group began coverage on shares of Insmed in a research report on Thursday, September 24th. They set a “buy” rating and a $188.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $196.52.
Read Our Latest Research Report on Insmed
Insider Activity
In related news, Director David Brennan sold 25,000 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the transaction, the director owned 39,238 shares in the company, valued at approximately $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.10% of the company’s stock.
Institutional Investors Weigh In On Insmed
A number of institutional investors have recently made changes to their positions in INSM. Pictet Asset Management Holding SA raised its position in shares of Insmed by 44.0% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock valued at $200,845,000 after acquiring an additional 537,188 shares in the last quarter. Bellevue Group AG lifted its stake in Insmed by 8.2% during the third quarter. Bellevue Group AG now owns 1,508,034 shares of the biopharmaceutical company’s stock worth $172,127,000 after purchasing an additional 114,616 shares during the last quarter. Sei Investments Co. boosted its holdings in Insmed by 56.8% in the first quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock worth $228,239,000 after purchasing an additional 505,624 shares during the period. Bank of New York Mellon Corp acquired a new position in Insmed in the second quarter worth $139,966,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Insmed by 480.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock worth $144,591,000 after purchasing an additional 1,048,518 shares during the period.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
Featured Stories
- Five stocks we like better than Insmed
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
